source
- Vitruvias Therapeutics recalls one lot of 30 mg thyroid tablets over super potency riskVitruvias Therapeutics announced a voluntary recall of a single lot (Lot No. 504950) of its 30 mg thyroid tablets to the consumer level. Testing confirmed the tablets could be superpotent, raising…
- Scribe Therapeutics’ early-stage IPO surges 43% as epigenetic cholesterol drug enters clinicScribe Therapeutics filed for an IPO while its lead epigenetic therapy moves into early clinical testing, a rare combination in a market that prefers later-stage, de-risked offerings. The company…